Betta Pushes Icotinib For China National Reimbursement List
This article was originally published in PharmAsia News
Icotinib, developed by Zhejiang Betta Pharmaceutical, is hailed as a success of China’s National Major New Drug Program, having obtained support from national and local governments during its research and development program.
You may also be interested in...
While Novartis is continuing to provide hydroxychloroquine for ongoing investigator-initiated trials and support for study of a potential vaccine, it has decided to stop sponsoring hydroxychloroquine clinical trials. Meanwhile, Natco has announced donations of chloroquine phosphate for clinical trials, while Centrient and Beximco have provided PPE for healthcare workers.
New chief medical officers take up positions at Abeona Therapeutics, Akcea Therapeutics and Oncologie, while there are new CFOs at Affimed, NGM Biopharmaceuticals, Phathom Pharmaceuticals, Oncologie and Syndax Pharmaceuticals.
Consumers in the UK can now self-select a version of Infirst's lipid-driven ibuprofen Flarin brand.